



## **Idera Pharmaceuticals to Present at BIO CEO Conference February 14th, 2012**

February 6, 2012 2:05 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2012-- Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer, is scheduled to present at the 14<sup>th</sup> Annual BIO CEO & Investor Conference on February 13<sup>th</sup> at 10:30 am ET. Dr. Agrawal will provide a review of Idera's Toll-like Receptor-targeted development programs in oncology and autoimmune diseases as well as its gene silencing oligonucleotide (GSO) technology.

The live webcast of the presentation will be available in the Investor section of Idera's website: [www.iderapharma.com](http://www.iderapharma.com). An archived version will also be available on the Company's website after the event for a limited time. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

### **About Idera Pharmaceuticals, Inc.**

Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The Company's TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases and cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit <http://www.iderapharma.com>.

Source: Idera Pharmaceuticals

### **Idera Pharmaceuticals, Inc.**

Lou Arcudi, 617-679-5517

[larcudi@iderapharma.com](mailto:larcudi@iderapharma.com)

or

MacDougall Biomedical Communications

Chris Erdman, 781-235-3060

[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)